

# MARKET REPORT



Ulcerative Colitis Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

**BioPortfolio**

Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



**GervanoRA**<sup>®</sup>

*We Assure Quality With Team Work*

# Ulcerative Colitis Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com)

# Ulcerative Colitis Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

GervanoRA's Pipeline Drug Analytics Report "Ulcerative Colitis Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020" provides a detailed overview on Ulcerative Colitis Competitive Space. Report provides deep insights on pipeline analytics outlook, drivers, restraints and unmet needs of Ulcerative Colitis pipeline drugs, Pipeline Analytics, Epidemiological Studies, Deals Analytics, Patent Analytics of Pipeline Drugs, Pipeline Drug Descriptions and Development Milestones, Clinical Trial Analytics, Competitive Landscape and Opportunity Assessments and Emerging Company Profiles.

## Pipeline Analytics Outlook:

Report summarize the comparative snapshots of all pipeline drugs as per the segments like stages of development, Geography, Route of Administration, Drug Class, Mechanism of Action, molecule type, target receptors and company types.

## Drivers, Restraints, Unmet Needs and Opportunities:

Report offers and provides a deep knowledge on the drivers, restraints and unmet needs and the opportunities derived upon a far-reaching study on the market trends and underlying factors affecting Ulcerative Colitis landscape.

## Pipeline Analytics:

The section covers all the molecules (drug candidates) in different stages of development (Discovery, Pre-clinical, Phase 1, Phase 2, Phase 3 and Pre-registration). It also offers information about the terminated and discontinued molecules. Analytics have been provided by Geography (covers major regions like the US, EU, Asia); by Route of Administration, by Drug Class and by Mechanism of Action. Report explains pipeline analytics by molecule type, target receptor and pipeline analytics by company type. Report also covers pipeline analytics by Universities and Institutes.

## Epidemiological Studies:

Our Senior Analysts for conducting Epidemiological Studies uses expertise and proprietary tools to understand the prevailing factors affecting the Disease population. Based on demographics, prevalent factors, incidence rate trends and many other geographical factors, Senior Analysts predicts the future numbers of the affected population over the forecast period, even suggesting the preventative measures.

## Deals Analytics:

The report bestows explicit information about the collaborations and partnering activities and trend in Ulcerative Colitis landscape, including details about different deals types like Mergers and Acquisitions, Licensing deals, Partnering deals, Collaboration Agreements, Series Financings, Grants and Fundings, etc occurring between 2010-2020.

## Patent Analytics of Pipeline Drugs:

The section even contains a thorough analysis on the intellectual property pertaining to Ulcerative Colitis pipeline drugs. Profound analytics have been provided related to the patent issuance and applications, patent expiries, patent extensions, etc to gain a complete knowledge on the new market entries filling up the gaps due to the patent expiries.

## Pipeline Drug Descriptions and Development Milestones:

Report provides detailed pipeline drugs descriptions covering all key aspects of the pipeline drugs like intended indications, mechanism of action, route of administration and role in pathophysiological conditions. Report even covers all development milestones of the pipeline drugs right from the early research and development to current stage of development.

#### Clinical Trial Analytics:

The report is inclusive of all the updated clinical trials information, providing details related to the completed clinical trials, ongoing clinical trials, planned clinical trials, even including complete analytics based on sponsors (companies, universities and institutes) involved in the development of Ulcerative Colitis Therapeutics.

#### Competitive Landscape and Opportunity Assessments:

The report is an absolute package covering all the companies - Established and emerging companies (Clinical-stage companies, pre-clinical stage companies, startups) actively involved in the R&D of new therapeutics for the treatment of Ulcerative Colitis. Report provided opportunity assessments by performing a competitive and comparative analysis on the top 20 Emerging companies in the competitive space.

#### Emerging Company Profiles:

Report features company profiles with data concentrated on: Partnering activities and patent analysis of the company, R&D efforts and advancements, Comparison of internal investment and external funding, Achievements of special regulatory allowances and Outline of in-licensing/out licensing opportunities.

## Additional Details

**Publisher** : Gervano R A

**Reference** : GERPH530

**Number of Pages** : 125

**Report Format** : PDF

**Publisher Information** :



GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.

GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we're playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

# Table Of Contents for Ulcerative Colitis Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

- CHAPTER 01: INTRODUCTION1.1. REPORT DESCRIPTION1.2. METHODOLOGY1.3. ABOUT US: GERVANORA DATA SERVICESCHAPTER 02: EXECUTIVE SUMMARY2.1. REPORT SUMMARY2.2. KEY EVENTS IN THE ULCERATIVE COLITIS COMPETITIVE SPACE2.3. REPORT MAJOR FINDINGS2.3.1. DRIVERS2.3.2. RESTRAINTS2.3.3. OPPORTUNITIESCHAPTER 03: PIPELINE ANALYTICS OUTLOOK3.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS3.1.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY STAGE OF DEVELOPMENT3.1.2. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY GEOGRAPHY3.1.3. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY ROUTE OF ADMINISTRATION3.1.4. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY DRUG CLASS3.1.5. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MECHANISM OF ACTION3.1.6. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULE TYPE3.1.7. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULAR TARGET3.1.8. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY COMPANY TYPE3.2. UNMET NEEDS AND MARKET DEMANDS3.2.1. UNMET NEEDS AND MARKET DEMANDS FOR NEWER THERAPIES3.2.2. UNMET NEEDS AND MARKET DEMANDS BY ROUTE OF ADMINISTRATION3.2.3. UNMET NEEDS AND MARKET DEMANDS BY GEOGRAPHY3.3 MARKET DYNAMICS OF ULCERATIVE COLITIS COMPETITIVE LANDSCAPECHAPTER 04: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES4.1. DISEASE DEFINITION AND SYMPTOMS4.2. DISEASE CAUSE AND PATHOPHYSIOLOGY4.3. DISEASE DIAGNOSIS4.4. TREATMENT ALGORITHM AND GUIDELINES4.5. EPIDEMIOLOGY STUDIES3.5.1. GLOBAL AND HISTORICAL TRENDS4.6. EPIDEMIOLOGY FORECAST4.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS4.6.2. PROBABILISTIC EPIDEMIOLOGY FORECASTCHAPTER 05: DEALS (M&A) ANALYTICS OF ULCERATIVE COLITIS COMPETITIVE LANDSCAPE4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)4.1.1 DEALS ANALYTICS BY DEAL TYPE4.1.1.1. COLLABORATION DEALS4.1.1.2. LICENSING DEALS4.1.1.3. FINANCING DEALS4.1.2 DEALS ANALYTICS BY ANNUAL FREQUENCY4.1.3 DEALS ANALYTICS BY ACTIVE PLAYERCHAPTER 06: PATENT ANALYTICS OF ULCERATIVE COLITIS PIPELINE DRUGS6.1. PATENT ANALYTICS BY GEOGRAPY6.2. PATENT ANALYTICS BY PATENT EXPIRY6.3. PATET ANALYTICS BY SPECIAL ALLOWANCES AND TERM EXTENSIONSCHAPTER 07: PIPELINE DRUGS ANALYTICS OF ULCERATIVE COLITIS7.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT5.1.1.1. PRE-REGISTRATION PIPELINE DRUGS5.1.2. PHASE III PIPELINE DRUGS5.1.3. PHASE II PIPELINE DRUGS5.1.4. PHASE I/II PIPELINE DRUGS5.1.5. PHASE I PIPELINE DRUGS5.1.6. PRE-CLINICAL PIPELINE DRUGS5.1.7. EARLY R&D PIPELINE DRUGS5.1.8. INACTIVE AND DISCONTINUED PIPELINE DRUGS5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY5.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION5.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS5.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION5.6. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE5.7. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS5.8. PIPELINE DRUGS ANALYTICS BY COMPANY TYPECHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES6.1. PRE-REGISTRATION PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES6.2. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES6.3. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES6.4. PHASE I/II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES6.5. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONESCHAPTER 09: ESTIMATED APPROVAL TIMELINES OF ULCERATIVE COLITIS PIPELINE DRUGS7.1. METHODOLOGY7.2. ESTIMATED APPROVAL TIMELINES US & EX-USCHAPTER 10: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING8.1. EXTERNAL DEPENDENCIES8.1.1. BUSINESS R&D - INTERNAL INVESTMENT AND EXTERNAL FUNDING8.2. PIPELINE PORTFOLIO8.3. EXPECTED MARKET ENTRIES8.4. PATENTS AND EXCLUSIVITY8.5. MARKET DYNAMICS AND PARTNERING8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES8.7. COMPANY DEVELOPMENTSCHAPTER 11: CURRENT AND FUTURE COMPETITIVE LANDSCAPE9.1. EMERGING COMPANIES9.1.1 EMERGING COMPANY PROFILES

# List Of Tables in Ulcerative Colitis Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

## LIST OF TABLES

- TABLE 01: ULCERATIVE COLITIS REPORT HIGHLIGHTS IN NUMERICALS
- TABLE 02: COLLABORATION DEALS IN ULCERATIVE COLITIS THERAPEUTIC AREA
- TABLE 03: LICENSING DEALS IN ULCERATIVE COLITIS THERAPEUTIC AREA
- TABLE 04: FINANCING DEALS IN ULCERATIVE COLITIS THERAPEUTIC AREA
- TABLE 5: ULCERATIVE COLITIS PHASE III PIPELINE MOLECULES
- TABLE 6: ULCERATIVE COLITIS PHASE II PIPELINE MOLECULES
- TABLE 7: ULCERATIVE COLITIS PHASE I/II PIPELINE MOLECULES
- TABLE 8: ULCERATIVE COLITIS PHASE I PIPELINE MOLECULES
- TABLE 9: PRECLINICAL STAGE DRUG CANDIDATES FOR ULCERATIVE COLITIS
- TABLE 10: LIST OF PIPELINE MOLECULES OF PARENTERAL ROUTE OF ADMINISTRATION
- TABLE 11: LIST OF PIPELINE MOLECULES OF ORAL ROUTE OF ADMINISTRATION
- (Remaining Tables can be seen in detailed Report)

# List Of Figures, Charts and Diagrams in Ulcerative Colitis Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

## LIST OF FIGURES

- FIGURE 01: KEY EVENTS IN THE ULCERATIVE COLITIS COMPETITIVE SPACE
- FIGURE 02: ULCERATIVE COLITIS DEAL ANALYTICS BY DEAL TYPE
- FIGURE 03: ULCERATIVE COLITIS DEAL ANALYTICS BY DEAL FREQUENCY
- FIGURE 04: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D
- FIGURE 05: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT
- FIGURE 06: ULCERATIVE COLITIS DRUGS PIPELINE ANALYTICS BY ROA
- FIGURE 07: ULCERATIVE COLITIS DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA
- FIGURE 08: PARENTERAL DRUGS PIPELINE ANALYTICS BY HSD
- FIGURE 09: ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
- FIGURE 10: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES
- FIGURE 11: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT
- FIGURE 12: ULCERATIVE COLITIS PIPELINE DRUGS BIOLOGICALS VS SMALL MOLECULES
- FIGURE 13: ULCERATIVE COLITIS PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE VS STAGE OF DEVELOPMENT
- FIGURE 14: ULCERATIVE COLITIS COMPANIES (NUMBER, PERCENT SHARE)
- FIGURE 15: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON ULCERATIVE COLITIS
- (Remaining Figures can be seen in detailed Report)



# How to Buy...

Ulcerative Colitis Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/270517>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com) We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$1063** | Single User Price
- \$1530** | Site License Price
- \$2125** | Global License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.